

PATENT
104610-55275

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the U.S. Patent No.: 7,385,061 B2
Issued June 10, 2008

Serial No. : 10/557,539

Filed : November 21, 2005

Title : FURAZANOBENZIMIDAZOLES

:
: Art Unit : 1626
:
: Examiner : Laura L. Stockton
:
:
:
:
:
:

Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Certificate
AUG 14 2008
of Correction

**REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT
FOR PATENT OFFICE MISTAKE (37 C.F.R. 1.322)**

Sir:

A certificate of correction under 35 U.S.C. 254 is requested for the above patent. It is noted that error appears in this patent of a clerical nature, as more fully described below. Correction thereof does not involve such changes in the patent as would constitute new matter or would require re-examination.

Attached hereto, in duplicate, is Form PTO/SB/44, with at least one copy being suitable for printing. Also enclosed is the listing of claims portion of the Substitute Amendment under 37 CFR 1.312 filed on January 23, 2008 and April 10, 2008 setting forth claim 39 in the application which matured into claim 17 of the subject patent. The error to be corrected appears on line 8, claim 17 of the subject patent. Claim 17 of the subject patent is claim 39 of the application. The error on line 8 of claim 17 of the subject patent is with respect to the portion of the name of the compound which reads "CH₂CH₂(CO)OH₃". This portion of the name should be --CH₂CH₂(CO)OH-- in accordance with claim 39 of this application.

The changes requested herein occurred as a result of printing the Letters Patent and the Certificate should be issued without expense to applicant under Rule 322 of the Rules of Practice. Accordingly, Applicant requests issuance of the Certificate of Correction.

RECEIVED-100 PTO
Patent Publication
AUG 14 2008

104610-55275)

If any additional fees are due in respect to this matter, please charge them to
Deposit Account No. 03-3839.

Please send the Certificate of Correction to:

William H. Epstein
Gibbons P.C.
One Gateway Center
Newark, NJ 07102-5310

Respectfully submitted,



William H. Epstein
Registration No. 20,008
Attorney for Applicant

Gibbons P.C.
One Gateway Center
Newark, NJ 07102-5310

RECEIVED-USPTO
Patent Publication

AUG 14 2008

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,385,061

APPLICATION NO. : 10/557,539

ISSUE DATE : June 10, 2008

INVENTOR(S) : Martin Eberle, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 76, line 25 (claim 17, line 8), please change " $\text{CH}_2\text{CH}_2(\text{CO})\text{OH}_3$ "
to read -- $\text{CH}_2\text{CH}_2(\text{CO})\text{OH}$ --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Section**
Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

AUG 14 2008

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**Page 1 of 1

PATENT NO. : 7,385,061

APPLICATION NO. : 10/557,539

ISSUE DATE : June 10, 2008

INVENTOR(S) : Martin Eberle, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 76, line 25 (claim 17, line 8), please change " $\text{CH}_2\text{CH}_2(\text{CO})\text{OH}_3$ "
to read $--\text{CH}_2\text{CH}_2(\text{CO})\text{OH}--$

MAILING ADDRESS OF SENDER (Please do not use customer number below):

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections**
Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED-USPTO
Patent Publication

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

AUG 14 2008



PATENT
104610-55275 (22009)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Patent Application of: :
Eberle et al. : Art Unit : 1626
Serial No. : 10/557,539 :
Filed : November 21, 2005 : Examiner : L. Stockton
Title : Furazanobenzimidazoles :

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

SUBSTITUTE AMENDMENT under 37 C.F.R. § 1.312

Dear Sir:

This Amendment is being filed in lieu of the Amendment filed April 10, 2008 in response to the Notice of Allowability mailed February 14, 2008. In accordance with 37 C.F.R. §1.312, please amend the above-identified application as follows. The listing of the Claims begins on page 2 and the Remarks begin on page 15:


RECEIVED-USPTO
Patent Publication

AUG 14 2008

LISTING OF CLAIMS:

Claims 1-22 Canceled.

23. (Previously Amended) A compound of the formula



(I)

wherein

R represents phenyl, naphthyl, thienyl, pyridinyl or pyridazinyl ring,

said phenyl ring being optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,

acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino,

dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino

wherein the two substituents on nitrogen form together with the nitrogen a

heterocyclcyl, lower alkylcarbonyl, formyl, carboxy, lower alkoxy carbonyl, cyano,

halogen, and nitro; and wherein two adjacent substituents are methylenedioxy;

and said pyridinyl or pyridazinyl being optionally substituted in one or two positions with lower alkoxy, amino, or halogen;

X is -O- or >C=Y, wherein Y is oxygen;

R¹ represents hydrogen, hydroxy-lower alkyl, cyano-lower alkyl, or lower alkyl-
carbonyl; and










R², R³, R⁴, R⁵ and R⁶ is hydrogen;

AUG 14 2008

or a pharmaceutically acceptable salt thereof.













24. (Previously Amended) The compound of claim 23 where X is $>C=Y$, wherein Y is oxygen, or it's pharmaceutically acceptable salts.

25. (Previously Amended) The compound of claim 24, which compounds are selected from the group consisting of the compounds 1, 5, 6, 11, 14, 15, 16, 19, 23, 29, 35, 41, 42, 44, 45, 46, 47, 48, 50, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 64, 65, 66, 67, 68, 69, 70, 72, 74, 76, 77, 78 and 79, which compounds are set forth according to the following table:

Compound	R	R ¹
1		H
5		(CO)CH ₃
6		CH ₂ CH ₂ CN
11		CH ₂ CH ₂ CH ₂ OH
14		H
15		H
16		H
19		H
23		H















RECEIVED-NOPTO
FIRST PUBLICATION

AUG 14 2008

29		H
35		H
41		H
42		H
44		H
45		H
46		CH ₂ CH ₂ CN
47		CH ₂ CH ₂ CN
48		CH ₂ CH ₂ CN
50		H
52		CH ₂ CH ₂ CH ₂ OH
53		H








RECEIVED AIRPTO
PUSH/PULL/STATION

AUG 14 2008

54		CH ₂ CH ₂ CN
55		H
56		CH ₂ CH ₂ CN
57		CH ₂ CH ₂ CN
58		CH ₂ CH ₂ CN
59		H
61		CH ₂ CH ₂ CN
62		H
64		H
65		H
66		H
67		H
68		H
69		CH ₂ CH ₂ CN

RECEIVED USPTO
PROM. PUBLICATION


AUG 14 2008

70		H
72		H
74		H
76		H
77		H
78		H
79		CH ₂ CH ₂ CN

or their pharmaceutically acceptable salts.














26. (Previously Submitted) The compound of claim 24 wherein R¹ represents hydrogen or cyano-lower alkyl.

27. (Previously Amended) The compound of claim 26 wherein the compounds are selected from the group consisting of the compounds 6, 15, 29, 42, 44, 45, 46, 47, 48, 50, 54, 56, 58, 61, 64, 65, 70, 78, and 79, which compounds are set forth according to the following table:

Compound	R	R ¹
6		CH ₂ CH ₂ CN






RECEIVED ACP TO
PUBLICATION

AUG 14 2008

15		H
29		H
42		H
44		H
45		H
46		CH ₂ CH ₂ CN
47		CH ₂ CH ₂ CN
48		CH ₂ CH ₂ CN
50		H
54		CH ₂ CH ₂ CN
56		CH ₂ CH ₂ CN
58		CH ₂ CH ₂ CN
61		CH ₂ CH ₂ CN

RECEIVED-UNIT
PUBLICATION

AUG 14 2008

64		H
65		H
70		H
78		H
79		CH ₂ CH ₂ CN

or their pharmaceutically acceptable salts.


28. (Previously Submitted) The compound of claim 24, wherein R is optionally substituted phenyl.

29. (Previously Submitted) The compound of Claim 28 wherein said compound is 4-[1-(4-aminophenacyl)-1H-benzimidazol-2-yl]-furazan-3-yl-N-(2-cyanoethyl)-amine or pharmaceutically acceptable salts thereof.

30. (Previously Submitted) The compound of claim 26 where the compound has the formula

RECEIVED USPTO
FROM PUBLICATION

AUG 14 2008



(I)

wherein

R is pyridinyl optionally substituted in one or two positions by lower alkoxy, amino, or halogen;

X is -C=Y; Y is oxygen ;

R¹ is cyano-lower alkyl or hydrogen and;

R², R³, R⁴, R⁵, R⁶ is hydrogen;

or a pharmaceutically acceptable salt thereof.

31. (Previously Submitted) The compound of Claim 30 wherein R¹ is cyano-lower alkyl.

32. (Currently Amended) The compound of Claim 31 wherein said compound is 4-[1-(6-amino-3-pyridylcarbonyl)methyl]-1H-benzimidazol-2-yl]-furazan-2-yl]-N-(2-cyanoethyl)-amine or its pharmaceutical acceptable salts.


33. (Previously Submitted) The compound of Claim 30 wherein R¹ is hydrogen.

34. (Currently Amended) The compound of Claim 33 wherein said compound is 4-[1-(6-amino-3-pyridylcarbonyl)methyl]-1H-benzimidazol-2-yl]-furazan-3-ylamine; or pharmaceutical acceptable salts thereof.

RESTRICTED TO
PATENT OFFICE

AUG 14 2008

35. (Previously Amended) The compound of claim 28 where said compound has the formula









which compound is selected from the group consisting of the compounds 7, 10, 88, 89, 92, 93, 94, 95, 96, 97, 101 and 103, which compounds are set forth according to the following table:

Compound	R	R ¹
7		H
10		CH ₂ CH ₂ CN
88		H
89		H
92		H
93		CH ₂ CH ₂ CN




RECEIVED-USPTO
FACILITATION

AUG 14 2008

94		CH ₂ CH ₂ CN
95		CH ₂ CH ₂ CN
96		H
97		H
101		H
103		H


or pharmaceutically acceptable salts thereof.

36. (Previously Amended) The compound of claim 35, which compound is selected from the group consisting of the compounds 89, 92, 94 and 101, which compound are set forth according to the following table:

Compound	R	R'
89		H
92		H
94		CH ₂ CH ₂ CN


NOPTO
Publication

AUG 14 2008

101		H
-----	---	---

or their pharmaceutically acceptable salts.

37. (Previously Amended) A compound of the formula (I)



wherein

R represents phenyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxy-carbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen a heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxy-carbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;

X is -C= Y and Y is nitrogen substituted by an alkoxy;



R¹ represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl;

AUG 14 2008

R², R³ and R⁶ represent hydrogen;


R⁴ and R⁵, independently of each other, represent hydrogen, lower alkyl or lower alkoxy;
or R⁴ and R⁵ together represent methylenedioxy; or
pharmaceutically acceptable salts thereof.

38. (Previously Amended) The compound of claim 37, which compound is selected from the group consisting of the compounds 18 and 22, which compounds are set forth according to the following table:

Compound	R	R ¹
18		H
22		H



or their pharmaceutically acceptable salts.

39. (Currently Amended) A compound selected from the group consisting of the Compounds 9 and 13, which compounds **are as represented by the following formula and** are set forth according to the following table:



wherein Y is oxygen

Serial No. 10/557,539
Art Unit 1626

Compound	R	R ¹
9		$\text{CH}_2\text{CH}_2(\text{CO})\text{OCH}_3$
13		$\text{CH}_2\text{CH}_2(\text{CO})\text{OH}$

or their pharmaceutically acceptable salts.

RECEIVED U.S. PATENT
OFFICE

AUG 14 2008

REMARKS

The foregoing amendments are made in response to the Notice of Allowability mailed February 14, 2008 with accompanying Examiner's Amendment. The Issue Fee for this application has not been paid as of the filing of this Amendment. Claims 23-39 remain in this application. The Claims as presented above reflect the Examiner's Amendment which included the addition of Claim 39. The foregoing amendments reflect the correction of inadvertencies in Claims 32 and 34 and a clarification in Claim 39. In each of Claims 32 and 34, "methyl" has been inserted into the expression "(-6-amino-3-pyridylcarbonyl)-" so that it reads "(-6-amino-3-pyridylcarbonylmethyl)-". It is clear that methyl was inadvertently omitted in the naming of the compounds claimed in view of the structural formula in Claim 23 wherein there is a methylene link between the "X" and the benzamidazol group. Claim 32 is further amended to correct a typographical error in that "-furazan-2-yl-" is corrected to read "-furazan-3-yl-". Again, it is clear from the structural formula in Claim 23 that the furazanyl group is substituted in the 3 position and not the 2-position. Finally, Claim 39 is amended to recite that the claimed compounds are as represented by the structural formula. These amendment do not introduce any new matter into the claims. Accordingly, it is respectfully requested that the foregoing amendments and these remarks be made of record in the above-identified patent application.

This Substitute Amendment is being filed because it has been discovered that, in four instances, amendments made by Examiner's Amendment were inadvertently omitted from the claims as presented above. These changes in the claims are not represented above as amendments because the claims were already amended in those instances, hence to represent them as amendments above would not be correct as, technically, they are not within the amendments presented under 37 C.F.R. § 1.312 herein. It is respectfully requested that the claims as presented above be considered in regard to the Amendments under 37 C.F.R. § 1.312. The changes made above inadvertently omitted from the Amendment previously filed are as follows:

AUG 14 2008

Serial No. 10/557,539
Art Unit 1626

Claim 23, line 10, "nitrogen heterocyclyl" is replaced with "nitrogen a heterocyclyl".

Claim 27, line 3, "64" is replaced with "64, 65".

Claim 28, line 1, "phenyl" is replaced with "optionally substituted phenyl".

Claim 37, line 10, "nitrogen heterocyclyl" is replaced with "nitrogen a heterocyclyl".

No fees are believed to be necessitated by the foregoing amendment. However, should this be in error, authorization is hereby given to charge Deposit Account No. 03-3839 for any underpayment, or to credit any overpayments thereto.

Telephone calls should be addressed to R. Hain Swope, Reg. No. 24,864, at (973) 596-4905 and fax communications should be sent directly to him at (973) 639-6357.

Respectfully submitted,

Gibbons P.C.

By /RHSwope/
R. Hain Swope - Reg. No. 24,864
Tel. No. (973) 564-4905
Fax No. (973) 639-6357

Date: April 15, 2008

Please address all correspondence regarding this application to Customer No. 26345.

**Intellectual Property Docket Administrator
Gibbons P.C.
One Gateway Center,
Newark, New Jersey 07102-5310**

RECEIVED
PATENT
FEDERAL BUREAU OF INVESTIGATION

AUG 14 2008



PATENT
104610-55275 (22009)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Patent Application of:
Eberle et al.

:
: Art Unit : 1626
:
: Examiner : L. Stockton
:
:

Serial No. : 10/557,539

Filed : November 21, 2005

Title : Furazanobenzimidazoles

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

AMENDMENT under 37 C.F.R. § 1.312

Dear Sir:

In response to the Notice of Allowability mailed February 14, 2008 and in accordance with 37 C.F.R. §1.312, please amend the above-identified application as follows. The listing of the Claims begins on page 2 and the Remarks begin on page 15:


RECEIVED USPTO
PATENT DIVISION

AUG 14 2008

LISTING OF CLAIMS:

Claims 1-22 Canceled.

23. (Previously Amended) A compound of the formula



(I)

wherein

R represents phenyl, naphthyl, thienyl, pyridinyl or pyridazinyl ring, said phenyl ring being optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocycle, lower alkylcarbonyl, formyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and said pyridinyl or pyridazinyl being optionally substituted in one or two positions with lower alkoxy, amino, or halogen;

X is -O- or >C=Y, wherein Y is oxygen;

R¹ represents hydrogen, hydroxy-lower alkyl, cyano-lower alkyl, or lower alkyl-carbonyl; and










R², R³, R⁴, R⁵ and R⁶ is hydrogen;

AUG 14 2008

or a pharmaceutically acceptable salt thereof.













24. (Previously Amended) The compound of claim 23 where X is $>C=Y$, wherein Y is oxygen, or its pharmaceutically acceptable salts.

25. (Previously Amended) The compound of claim 24, which compounds are selected from the group consisting of the compounds 1, 5, 6, 11, 14, 15, 16, 19, 23, 29, 35, 41, 42, 44, 45, 46, 47, 48, 50, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 64, 65, 66, 67, 68, 69, 70, 72, 74, 76, 77, 78 and 79, which compounds are set forth according to the following table:

Compound	R	R ¹
1		H
5		(CO)CH ₃
6		CH ₂ CH ₂ CN
11		CH ₂ CH ₂ CH ₂ OH
14		H
15		H
16		H
19		H
23		H















RECEIVED
AUG 14 2008

AUG 14 2008

29		H
35		H
41		H
42		H
44		H
45		H
46		CH ₂ CH ₂ CN
47		CH ₂ CH ₂ CN
48		CH ₂ CH ₂ CN
50		H
52		CH ₂ CH ₂ CH ₂ OH
53		H








RECEIVED OCTO
10 14 2008

AUG 14 2008

54		CH ₂ CH ₂ CN
55		H
56		CH ₂ CH ₂ CN
57		CH ₂ CH ₂ CN
58		CH ₂ CH ₂ CN
59		H
61		CH ₂ CH ₂ CN
62		H
64		H
65		H
66		H
67		H
68		H
69		CH ₂ CH ₂ CN

RECEIVED
AUG 14 2003


AUG 14 2003

70		H
72		H
74		H
76		H
77		H
78		H
79		CH ₂ CH ₂ CN

or their pharmaceutically acceptable salts.














26. (Previously Submitted) The compound of claim 24 wherein R¹ represents hydrogen or cyano-lower alkyl.

27. (Previously Amended) The compound of claim 26 wherein the compounds are selected from the group consisting of the compounds 6, 15, 29, 42, 44, 45, 46, 47, 48, 50, 54, 56, 58, 61, 64, 70, 78 and 79, which compounds are set forth according to the following table:

Compound	R	R ¹
6		CH ₂ CH ₂ CN






RECEIVED-10/17/08
FBI/DOJ

AUG 14 2008

15		H
29		H
42		H
44		H
45		H
46		CH ₂ CH ₂ CN
47		CH ₂ CH ₂ CN
48		CH ₂ CH ₂ CN
50		H
54		CH ₂ CH ₂ CN
56		CH ₂ CH ₂ CN
58		CH ₂ CH ₂ CN
61		CH ₂ CH ₂ CN

RECEIVED 10/10/08
PATENT & TRADEMARK OFFICE

AUG 14 2008

64		H
65		H
70		H
78		H
79		CH ₂ CH ₂ CN

or their pharmaceutically acceptable salts.


28. (Previously Submitted) The compound of claim 24, wherein R is phenyl.

29. (Previously Submitted) The compound of Claim 28 wherein said compound is 4-[1-(4-aminophenacyl)-1H-benzimidazol-2-yl]-furazan-3-yl-N-(2-cyanoethyl)-amine or pharmaceutically acceptable salts thereof.

30. (Previously Submitted) The compound of claim 26 where the compound has the formula

RECEIVED AUG 14 2008

AUG 14 2008



(I)

wherein

R is pyridinyl optionally substituted in one or two positions by lower alkoxy, amino, or halogen;

X is -C=Y; Y is oxygen ;

R¹ is cyano-lower alkyl or hydrogen and;

R², R³, R⁴, R⁵, R⁶ is hydrogen;

or a pharmaceutically acceptable salt thereof.

31. (Previously Submitted) The compound of Claim 30 wherein R¹ is cyano-lower alkyl.


32. (Currently Amended) The compound of Claim 31 wherein said compound is 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-~~2~~**3**-yl]-N-(2-cyanoethyl)-amine or its pharmaceutical acceptable salts.

33. (Previously Submitted) The compound of Claim 30 wherein R¹ is hydrogen.

34. (Currently Amended) The compound of Claim 33 wherein said compound is 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-ylamine; or pharmaceutical acceptable salts thereof.

AUG 14 2008







35. (Previously Amended) The compound of claim 28 where said compound has the formula



which compound is selected from the group consisting of the compounds 7, 10, 88, 89, 92, 93, 94, 95, 96, 97, 101 and 103, which compounds are set forth according to the following table:




Compound	R	R ¹
7		H
10		CH ₂ CH ₂ CN
88		H
89		H
92		H
93		CH ₂ CH ₂ CN

AUG 14 2008


94		CH ₂ CH ₂ CN
95		CH ₂ CH ₂ CN
96		H
97		H
101		H
103		H

or pharmaceutically acceptable salts thereof.

36. (Previously Amended) The compound of claim 35, which compound is selected from the group consisting of the compounds 89, 92, 94 and 101, which compound are set forth according to the following table:


Compound	R	R ¹
89		H
92		H
94		CH ₂ CH ₂ CN

AUG 14 2008

101		H
-----	---	---

or their pharmaceutically acceptable salts.

37. (Previously Amended) A compound of the formula (I)



wherein

R represents phenyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;

X is -C= Y and Y is nitrogen substituted by an alkoxy;

R¹ represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl;



RECEIVED-UPPTO
PATENT OFFICE

AUG 14 2008

R², R³ and R⁶ represent hydrogen;


R⁴ and R⁵, independently of each other, represent hydrogen, lower alkyl or lower alkoxy;
or R⁴ and R⁵ together represent methylenedioxy; or
pharmaceutically acceptable salts thereof.

38. (Previously Amended) The compound of claim 37, which compound is selected from the group consisting of the compounds 18 and 22, which compounds are set forth according to the following table:

Compound	R	R ¹
18		H
22		H

or their pharmaceutically acceptable salts.



39. (Currently Amended) A compound selected from the group consisting of the Compounds 9 and 13, which compounds **are as represented by the following formula and** are set forth according to the following table:



wherein Y is oxygen

RECEIVED USPTO
Patent Division

AUG 14 2008

Compound	R	R ¹
9		CH ₂ CH ₂ (CO)OCH ₃
13		CH ₂ CH ₂ (CO)OH

or their pharmaceutically acceptable salts.

RECEIVED
FBI LABORATORY

AUG 14 2008

REMARKS

The foregoing amendments are made in response to the Notice of Allowability mailed February 14, 2008 with accompanying Examiner's Amendment. The Issue Fee for this application has not been paid as of the filing of this Amendment. Claims 23-39 remain in this application. The Claims as presented above reflect the Examiner's Amendment which included the addition of Claim 39. The foregoing amendments reflect the correction of inadvertencies in Claims 32 and 34 and a clarification in Claim 39. In each of Claims 32 and 34, "methyl" has been inserted into the expression "(-6-amino-3-pyridylcarbonyl)-" so that it reads "(-6-amino-3-pyridylcarbonylmethyl)-". It is clear that methyl was inadvertently omitted in the naming of the compounds claimed in view of the structural formula in Claim 23 wherein there is a methylene link between the "X" and the benzamidazol group. Claim 32 is further amended to correct a typographical error in that "-furazan-2-yl-" is corrected to read "-furazan-3-yl-". Again, it is clear from the structural formula in Claim 23 that the furazanyl group is substituted in the 3 position and not the 2-position. Finally, Claim 39 is amended to recite that the claimed compounds are as represented by the structural formula. These amendment do not introduce any new matter into the claims. Accordingly, it is respectfully requested that the foregoing amendments and these remarks be made of record in the above-identified patent application.

No fees are believed to be necessitated by the foregoing amendment. However, should this be in error, authorization is hereby given to charge Deposit Account No. 03-3839 for any underpayment, or to credit any overpayments thereto.

Telephone calls should be addressed to R. Hain Swope, Reg. No. 24,864, at (973) 596-4905 and fax communications should be sent directly to him at (973) 639-6357.


AUG 14 2008

Serial No. 10/557,539
Art Unit 1626

Respectfully submitted,

Gibbons P.C.

By


R. Hain Swope - Reg. No. 24,864

Tel. No. (973) 564-4905

Fax No. (973) 639-6357

Date: April 10, 2008

Please address all correspondence regarding this application to **Customer No. 26345.**

**Intellectual Property Docket Administrator
Gibbons P.C.
One Gateway Center,
Newark, New Jersey 07102-5310**

RECEIVED-USPTO
PATENT DIVISION

AUG 14 2008